ArticleACS pharmacology & translational science2025
A Therapeutic Small-Interfering RNA Potentiates Janus Kinase 1 Modulation for the Treatment of Dog Inflammatory Diseases.
Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Inflammatory cytokine signaling pathways share notable similarities between humans and dogs. Janus kinase (JAK) family enzymesJAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2) are popular therapeutic targets for inflammatory diseases in human clinics. While more than a dozen JAK inhibitors are available for human use, the only FDA-approved JAK inhibitor for dogs is oclacitinib. Oclacitinib targets multiple JAK subtypes (i.e., JAK1/2/3 and TYK2) and requires daily oral administration, raising concerns about its long-term safety. There is a growing demand for safer and longer-lasting JAK inhibitors to improve the treatment of dog inflammatory diseases. Small-interfering RNAs (siRNAs) are an emerging class of medicines that offer mRNA sequence-specific target selectivity and sustained durability. In this work, we developed a fully chemically modified siRNA that supports efficient gene silencing of dog JAK1. We show that dog JAK1 siRNA offers more than 90% target silencing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.